Avenue Therapeutics Faces Delisting Notice
Ticker: ATXI · Form: 8-K · Filed: Mar 17, 2025 · CIK: 1644963
| Field | Detail |
|---|---|
| Company | Avenue Therapeutics, INC. (ATXI) |
| Form Type | 8-K |
| Filed Date | Mar 17, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory-filing
Related Tickers: AVTX
TL;DR
AVTX got a delisting warning, might be in trouble with the exchange.
AI Summary
Avenue Therapeutics, Inc. filed an 8-K on March 17, 2025, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The company is incorporated in Delaware and its principal executive offices are located at 1111 Kane Concourse, Suite 301, Bay Harbor Islands, Florida.
Why It Matters
This filing indicates potential issues with Avenue Therapeutics' compliance with stock exchange listing requirements, which could impact its stock trading and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's continued trading on an exchange.
Key Players & Entities
- Avenue Therapeutics, Inc. (company) — Registrant
- March 17, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of Incorporation
- 1111 Kane Concourse, Suite 301, Bay Harbor Islands, Florida 33154 (address) — Principal Executive Offices
- 781-652-4500 (phone_number) — Registrant's telephone number
FAQ
What specific listing rule or standard has Avenue Therapeutics failed to satisfy?
The filing does not specify the exact rule or standard that Avenue Therapeutics has failed to satisfy, only that a notice has been received.
What is the immediate impact of this notice on Avenue Therapeutics' stock trading?
The filing indicates a potential delisting, which could lead to the stock trading on a different exchange or over-the-counter, impacting liquidity and investor access.
Does this filing provide a timeline for addressing the listing deficiency?
No, this 8-K filing serves as a notification of the issue and does not include details on a specific timeline for resolution.
What are the potential consequences if Avenue Therapeutics cannot rectify the situation?
If the situation is not rectified, the company's securities could be delisted from the stock exchange, significantly affecting its marketability.
Where are Avenue Therapeutics' principal executive offices located?
Avenue Therapeutics, Inc.'s principal executive offices are located at 1111 Kane Concourse, Suite 301, Bay Harbor Islands, Florida 33154.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 17, 2025 regarding AVENUE THERAPEUTICS, INC. (ATXI).